BR0011503A - Indução do fator de crescimento endotelial vascular (vdgf) pela proteìna de serina/treonina cinase akt - Google Patents

Indução do fator de crescimento endotelial vascular (vdgf) pela proteìna de serina/treonina cinase akt

Info

Publication number
BR0011503A
BR0011503A BR0011503-7A BR0011503A BR0011503A BR 0011503 A BR0011503 A BR 0011503A BR 0011503 A BR0011503 A BR 0011503A BR 0011503 A BR0011503 A BR 0011503A
Authority
BR
Brazil
Prior art keywords
induction
growth factor
vdgf
vascular endothelial
endothelial growth
Prior art date
Application number
BR0011503-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Kun Guo
Yuri Ivashchenko
Kenneth Clark
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of BR0011503A publication Critical patent/BR0011503A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0011503-7A 1999-06-11 2000-06-01 Indução do fator de crescimento endotelial vascular (vdgf) pela proteìna de serina/treonina cinase akt BR0011503A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13872499P 1999-06-11 1999-06-11
GB9926058 1999-11-03
PCT/US2000/015098 WO2000077190A2 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Publications (1)

Publication Number Publication Date
BR0011503A true BR0011503A (pt) 2002-03-05

Family

ID=26316052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011503-7A BR0011503A (pt) 1999-06-11 2000-06-01 Indução do fator de crescimento endotelial vascular (vdgf) pela proteìna de serina/treonina cinase akt

Country Status (17)

Country Link
EP (1) EP1187911A2 (cs)
JP (1) JP2003530818A (cs)
KR (1) KR20020012270A (cs)
CN (1) CN1360629A (cs)
AU (1) AU773450B2 (cs)
BR (1) BR0011503A (cs)
CA (1) CA2376630A1 (cs)
CZ (1) CZ20014444A3 (cs)
HK (1) HK1041500A1 (cs)
HU (1) HUP0201663A3 (cs)
IL (1) IL146730A0 (cs)
MX (1) MXPA01012748A (cs)
NO (1) NO20016025L (cs)
NZ (1) NZ516054A (cs)
PL (1) PL352859A1 (cs)
SI (1) SI20978A (cs)
WO (1) WO2000077190A2 (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE402995T1 (de) * 1999-03-19 2008-08-15 Aventis Pharma Inc Akt-3 nukleinsäure, polypeptide und deren verwendung
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
MXPA01010459A (es) 1999-04-16 2003-08-20 Univ Yale Mutaciones de sintasa de oxido nitrico endotelial, utiles para terapia con genes y su depuracion terapeutica.
US6187586B1 (en) * 1999-12-29 2001-02-13 Isis Pharmaceuticals, Inc. Antisense modulation of AKT-3 expression
ATE284701T1 (de) * 2000-03-02 2005-01-15 Ludwig Inst Cancer Res Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE402995T1 (de) * 1999-03-19 2008-08-15 Aventis Pharma Inc Akt-3 nukleinsäure, polypeptide und deren verwendung

Also Published As

Publication number Publication date
WO2000077190A2 (en) 2000-12-21
NO20016025L (no) 2002-02-08
JP2003530818A (ja) 2003-10-21
NZ516054A (en) 2004-04-30
NO20016025D0 (no) 2001-12-10
PL352859A1 (en) 2003-09-08
AU5175800A (en) 2001-01-02
AU773450B2 (en) 2004-05-27
KR20020012270A (ko) 2002-02-15
CZ20014444A3 (cs) 2002-05-15
EP1187911A2 (en) 2002-03-20
IL146730A0 (en) 2002-07-25
MXPA01012748A (es) 2002-07-02
HK1041500A1 (zh) 2002-07-12
HUP0201663A2 (en) 2002-08-28
HUP0201663A3 (en) 2005-01-28
WO2000077190A3 (en) 2001-04-12
SI20978A (sl) 2003-02-28
CN1360629A (zh) 2002-07-24
CA2376630A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
ATE309194T1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BR0206955A (pt) Ligantes de receptores de canabinóides
PL361341A1 (pl) Nowa kompozycja farmaceutyczna
SE9800836D0 (sv) New Compounds
BR0116047A (pt) Imidazoquinolinas substituìdas de éter heterocìclico
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
SI1536827T1 (sl) Uporaba protein-kinaze n beta
BR0203172A (pt) Agentes terapêuticos para acondroplasia
BRPI0407999A (pt) compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf)
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
BR0012450A (pt) Benzimidazóis substituìdos
WO2003020217A3 (en) Novel pyrazole analogs acting on cannabinoid receptors
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
WO2003035005A3 (en) Heteroindanes: a new class of potent cannabimimetic ligands
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
NO20040511L (no) Aminoisoxazolderivater som kinaseinhibitorer
SE9903544D0 (sv) Novel compounds
BR9911861A (pt) Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
CA2447924A1 (en) Olopatadine formulations for topical administration
BR0314182A (pt) Formulações compreendendo um composto de indolinona
BR0213292A (pt) tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.